See how top analysts and institutions rate GENI — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| Roth Capital | Initiated | Buy | $16 | 2025-09-12 |
| Northland Capital | Initiated | Outperform | $14 | 2025-07-25 |
| Arete | Initiated | Buy | $15 | 2025-07-09 |
| Truist | Initiated | Buy | $14 | 2025-07-01 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 2 | 15 | 1 | 0 | 0 |
| October 2025 | 2 | 15 | 1 | 0 | 0 |
| September 2025 | 2 | 15 | 1 | 0 | 0 |
| August 2025 | 2 | 14 | 1 | 0 | 0 |
The majority of institutional investors have issued a "Buy" rating for GENI, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
